Valuation: iCAD Inc

Market Cap 106M 90.41M 84.35M 77.4M 145M 10.1B 148M 1B 390M 5.06B 396M 388M 16.76B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 75.99M 70.9M 65.05M 122M 8.49B 125M 841M 328M 4.26B 333M 326M 14.09B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer 61 10/03/2023
Director of Finance/CFO 54 17/07/2025
Corporate Secretary - 17/07/2025
Change 5-day change 1-year change 3-year change Capi.($)
-1.18%+5.66%+28.49%+16.78% 232B
0.00%+6.48%+5.72%-13.83% 152B
+1.12%-4.30%-19.65%+31.70% 132B
+1.05%-3.92%-52.67%-1.23% 71.55B
-0.13%-1.87%+10.76%+17.76% 51.78B
+0.55%+1.78%-16.28%-12.03% 51.75B
+0.50%+6.11%+34.54%+32.60% 44.14B
+0.10%-1.47%+39.82%+52.00% 39.76B
+0.35%+0.99%+1.74%+7.90% 33.45B
Average +0.25%+0.46%+3.61%+14.63% 89.84B
Weighted average by Cap. -0.01%+1.38%+4.94%+12.33%

Financials

2023 2024
Net sales 17.32M 14.83M 13.83M 12.69M 23.85M 1.66B 24.32M 164M 63.98M 830M 65.03M 63.61M 2.75B 19.61M 16.79M 15.66M 14.37M 27.01M 1.88B 27.54M 186M 72.44M 940M 73.62M 72.02M 3.11B
Net income -4.85M -4.15M -3.87M -3.55M -6.68M -464M -6.81M -45.93M -17.91M -232M -18.2M -17.8M -769M -5.62M -4.81M -4.49M -4.12M -7.74M -537M -7.89M -53.22M -20.75M -269M -21.09M -20.63M -892M
Net Debt -21.21M -18.16M -16.94M -15.55M -29.21M -2.03B -29.79M -201M -78.35M -1.02B -79.64M -77.9M -3.37B -16.84M -14.42M -13.46M -12.35M -23.2M -1.61B -23.66M -160M -62.23M -808M -63.25M -61.87M -2.67B
Logo iCAD Inc
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
-